Find the latest taysha gene therapies, inc On november 13, piper sandler analyst biren amin reaffirmed his buy rating on taysha gene therapies, assigning a $9. (tsha) stock quote, history, news and other vital information to help you with your stock trading and investing.
Taysha Sativa (@petitesativaxxx) / Twitter
A detailed overview of taysha gene therapies, inc
At taysha, we are focused on developing gene therapies that hold promise to significantly improve outcomes and quality of life for those patients
Our gene therapy candidates are designed to target the unique underlying biology of cns diseases. In november 2025, taysha gene therapies announced the appointment of david mcninch as chief commercial officer, reported a third quarter net loss of us$32.73 million with a sales decline to us$4.29 million for the nine months, and filed a us$200 million shelf registration to offer a variety of securities Common stock (tsha) stock prices, quotes, historical data, news, and insights for informed trading and investment decisions.
